Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR-Reference-Cited by-同舟云学术

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR

Published:2018-05-01 Issue:5 Volume:154 Page:581
ISSN:2168-6068
Container-title:JAMA Dermatology
language:en
Short-container-title:JAMA Dermatol

Author:

Mason Kayleigh J.¹,Barker Jonathan N. W. N.²,Smith Catherine H.²,Hampton Philip J.³,Lunt Mark¹,McElhone Kathleen¹,Warren Richard B.¹⁴,Yiu Zenas Z. N.⁴⁵,Griffiths Christopher E. M.¹⁴,Burden A. David⁶,

Affiliation:

1. Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom

2. St John's Institute of Dermatology, Guy's and St Thomas’ NHS Foundation Trust, London, United Kingdom

3. Newcastle Dermatology, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom

4. Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom

5. Centre for Pharmacoepidemiology and Drug Safety, The University of Manchester, Manchester, United Kingdom

6. Department of Dermatology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Dermatology

Reference21 articles.

1. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.;Garcia-Doval;Arch Dermatol,2012

2. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.;Schmitt;Br J Dermatol,2008

3. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response.;Eichler;Nat Rev Drug Discov,2011

4. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives.;Burden;Br J Dermatol,2012

5. Etanercept as monotherapy in patients with psoriasis.;Leonardi;N Engl J Med,2003

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO);Acta Dermato-Venereologica;2024-09-05

2. Improving systemic therapy selection for inflammatory skin diseases: A clinical need survey;JAAD International;2024-09

3. A Comprehensive Review of the Factors Affecting the Redefinition of Therapeutic Use in Metropolitan Cities during the Emerging and Re-emerging Pandemics;Romanian Journal of Military Medicine;2024-09-01

4. Investigating EGFR, BRAF, and RAS Mutations in Oral and Cutaneous Squamous Cell Neoplasms: A Preliminary Report on Romanian Patients;Romanian Journal of Military Medicine;2024-09-01

5. Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry;Advances in Therapy;2024-08-29